S
14.22
-0.11 (-0.77%)
| Penutupan Terdahulu | 14.33 |
| Buka | 14.19 |
| Jumlah Dagangan | 1,437,092 |
| Purata Dagangan (3B) | 1,745,450 |
| Modal Pasaran | 1,396,597,376 |
| Harga / Jualan (P/S) | 15.99 |
| Harga / Buku (P/B) | 5.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| Margin Keuntungan | 8.97% |
| Margin Operasi (TTM) | 54.51% |
| EPS Cair (TTM) | 0.080 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4,900.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.04% |
| Nisbah Semasa (MRQ) | 14.26 |
| Aliran Tunai Operasi (OCF TTM) | 13.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 8.96 M |
| Pulangan Atas Aset (ROA TTM) | -0.66% |
| Pulangan Atas Ekuiti (ROE TTM) | 3.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | ARS Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.7
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.70 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 22.97% |
| % Dimiliki oleh Institusi | 75.59% |
| Julat 52 Minggu | ||
| Median | 30.00 (110.97%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Scotiabank | 07 Mar 2025 | 30.00 (110.97%) | Beli | 10.85 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FITZPATRICK ALEXANDER A | - | 14.33 | -102,969 | -1,475,546 |
| SAUNDERS BRENT L | - | 14.33 | -120,000 | -1,719,600 |
| SCOTT KATHLEEN D. | - | 14.33 | -50,000 | -716,500 |
| Jumlah Keseluruhan Kuantiti Bersih | -272,969 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,911,646 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 14.33 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FITZPATRICK ALEXANDER A | Pegawai | 20 May 2025 | Jual (-) | 102,969 | 14.33 | 1,475,546 |
| FITZPATRICK ALEXANDER A | Pegawai | 20 May 2025 | Pelaksanaan pilihan | 100,000 | - | - |
| SAUNDERS BRENT L | Pengarah | 20 May 2025 | Jual (-) | 120,000 | 14.33 | 1,719,600 |
| SAUNDERS BRENT L | Pengarah | 20 May 2025 | Pelaksanaan pilihan | 120,000 | - | - |
| SCOTT KATHLEEN D. | Pegawai | 20 May 2025 | Jual (-) | 50,000 | 14.33 | 716,500 |
| SCOTT KATHLEEN D. | Pegawai | 20 May 2025 | Pelaksanaan pilihan | 50,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |